Skip to main content

Table 2 (abstract O17). Monthly migraine headache days with acute medication use, average of months 1-6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  LFEM HFEM  
Treatment Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb p-valuec
Placebo 4.8 (1.7) 295 -0.8 ± 0.2    8.9 (3.3) 580 -2.7 ± 0.2    
Galca 120mg 4.8 (1.8) 150 -2.4 ± 0.2 -1.7 ± 0.2 <.001 8.8 (3.4) 286 -4.6 ± 0.2 -1.9 ± 0.2 <.001 .493
Galca 240mg 4.9 (1.7) 145 -2.1 ± 0.2 -1.4 ± 0.2 <.001 8.7 (3.1) 283 -4.6 ± 0.2 -1.9 ± 0.2 <.001 .152
  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; b p-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo